Symetis' CE Mark win puts it among the ranks of Medtronic and Edwards Lifesciences as the only companies offering a TAVI system with both transapical and transfemoral delivery options.
Stealthy Swiss device maker Symetis announced today that it's launching commercial sales of its Acurate neo transfemoral transcatheter aortic valve implantation system, having just won CE Mark approval from European regulators.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/WU3Rkm
Cap comentari:
Publica un comentari a l'entrada